Beam Therapeutics Inc.
BEAM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $10 | $8 | $7 | $30 |
| % Growth | 14.6% | 13.3% | -75.2% | – |
| Cost of Goods Sold | $110 | $102 | $99 | $101 |
| Gross Profit | -$100 | -$93 | -$91 | -$71 |
| % Margin | -1,031.9% | -1,102% | -1,222.8% | -237.4% |
| R&D Expenses | $110 | $102 | $99 | $101 |
| G&A Expenses | $27 | $27 | $28 | $29 |
| SG&A Expenses | $27 | $27 | $28 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$110 | -$102 | -$99 | -$101 |
| Operating Expenses | $27 | $27 | $28 | $29 |
| Operating Income | -$127 | -$120 | -$119 | -$100 |
| % Margin | -1,307.6% | -1,419.2% | -1,596.9% | -332.7% |
| Other Income/Exp. Net | $14 | $18 | $10 | $10 |
| Pre-Tax Income | -$113 | -$102 | -$109 | -$90 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$113 | -$102 | -$109 | -$90 |
| % Margin | -1,162.4% | -1,208.3% | -1,462.8% | -300.5% |
| EPS | -1.1 | -1 | -1.24 | -1.09 |
| % Growth | -10% | 19.4% | -13.8% | – |
| EPS Diluted | -1.1 | -1 | -1.24 | -1.09 |
| Weighted Avg Shares Out | 103 | 102 | 88 | 83 |
| Weighted Avg Shares Out Dil | 103 | 102 | 88 | 83 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $0 | $10 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | $6 | $6 | $5 |
| EBITDA | -$107 | -$115 | -$114 | -$95 |
| % Margin | -1,105.1% | -1,353.8% | -1,522.9% | -314.6% |